S
Soligenix, Inc. (SNGX)
NCM – Real vaqt narxi. Valyuta: USD
0.31
+0.03 (10.57%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.31
+0.00 (0.10%)
Bozor oldidan: May 13, 2026, 7:44 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.31
+0.03 (10.57%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.31
+0.00 (0.10%)
Bozor oldidan: May 13, 2026, 7:44 AM EDT
Soligenix, Inc., kechki bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda kam uchraydigan kasalliklarni davolash uchun mahsulotlarni ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya ikkita segment orqali faoliyat yuritadi: Ixtisoslashtirilgan bioterapevtika va Jamoat salomatligi yechimlari. Ixtisoslashtirilgan bioterapevtika segmenti SGX301 (HyBryte) ni ishlab chiqadi, bu fotodinamik terapiya bo'lib, u teri T-hujayrali limfomasini davolash uchun 3-bosqichli klinik sinovni yakunlagan; SGX942, tug'ma immunitet regulyatori (IDR) texnologiyasi, 3-bosqichli klinik sinovda, shu jumladan bosh va bo'yin saratoni natijasida yuzaga keladigan og'iz mukozitini davolash uchun; SGX945, IDR texnologiyasi, Behchet kasalligida aftoz yaralarni davolash uchun 2a-bosqichli tadqiqotda; va SGX302, IDR texnologiyasi, engil va o'rtacha psoriazni davolash uchun 2a-bosqichli tadqiqotda. Jamoat salomatligi yechimlari segmenti 1a, 1b va 1c klinik sinovlarini yakunlagan zarin toksini vaktsina nomzodi RiVaxni ishlab chiqish bilan shug'ullanadi; SGX943, antibiotikka chidamli va yangi yuqumli kasalliklarni davolash uchun preklinik tadqiqotlarda terapevtik nomzod; ThermoVax, vaktsinalarni termostabilizatsiya qilish uchun preklinik rivojlanishdagi texnologiya; CiVax, COVID-19 ni oldini olish uchun vaktsina nomzodi; va Marburg va Ebola kabi filoviruslarga qaratilgan vaktsina dasturlari. Kompaniya ilgari DOR BioPharma, Inc. nomi bilan tanilgan va 2009 yil sentyabr oyida Soligenix, Inc. nomini o'zgartirgan. Soligenix, Inc. 1987 yilda ro'yxatga olingan va Nyu-Jersi shtatining Prinston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher J. Schaber Ph.D. | Chairman of the Board of Directors, CEO & President |
| Dr. Oreola Donini Ph.D. | Senior VP & Chief Scientific Officer |
| Dr. Richard C. Straube M.D., MSc. | Consulting Chief Medical Officer |
| Mr. Adam T. Rumage | Senior VP of Project Management & Regulatory Affairs |
| Mr. Jonathan L. Guarino CPA, CGMA | Senior VP, CFO & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-28 | 8-K | sngx-20260428x8k.htm |
| 2026-03-31 | POS AM | sngx-20251231xposam.htm |
| 2026-03-31 | 10-K | sngx-20251231x10k.htm |
| 2026-02-12 | 8-K | sngx-20260212x8k.htm |
| 2025-11-18 | 8-K | sngx-20251118x8k.htm |
| 2025-11-07 | 10-Q | sngx-20250930x10q.htm |
| 2025-09-29 | 8-K | sngx-20250925x8k.htm |
| 2025-09-23 | CORRESP | filename1.htm |
| 2025-09-19 | S-1 | sngx-20250630xs1.htm |
| 2025-08-27 | DRS | filename1.htm |